Core Insights - Plus Therapeutics, Inc. is advancing its ReSPECT-LM dose optimization trial for REYOBIQ, targeting leptomeningeal metastases (LM) with initial patient treatments underway [1][2] - The trial aims to identify optimal dosing regimens to maximize efficacy and safety, building on positive results from a previous Phase 1 study [3][4] - The company anticipates rapid enrollment due to the lack of FDA-approved therapies for LM and expects to complete Cohort 1 by the end of the year [2][4] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers [11] - The company’s lead product, REYOBIQ, is designed to deliver high-dose radiation directly to CNS tumors, potentially improving patient outcomes compared to existing therapies [8][11] - The ReSPECT-LM trial is supported by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), a significant funding source for cancer research [6][9] Clinical Trial Details - The ReSPECT-LM trial's primary objectives include determining the safety and tolerability of multiple REYOBIQ doses and identifying the maximum tolerated dose and minimum effective dose [3] - The previous Phase 1 trial demonstrated that a single dose of REYOBIQ could deliver an average absorbed dose of over 250 Gy, with significant tumor reduction observed in patients [4] - Data from the completed Phase 1 study will be presented at the upcoming SNO/ASCO CNS Metastases Conference in August 2025 [5] Industry Context - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with limited treatment options available, highlighting the need for innovative therapies [7] - REYOBIQ is being evaluated for multiple indications, including recurrent glioblastoma and pediatric brain cancer, indicating a broad potential application in CNS oncology [8][9]

Core Insights - Plus Therapeutics presented new data on its lead drug REYOBIQ™ at the Nuclear Medicine and Neurooncology Conference, highlighting its potential in treating Leptomeningeal Metastases (LM) [1][2] Group 1: REYOBIQ™ Data Presentation - The data indicates safety and clinical benefits of REYOBIQ in patients with LM, with multiple doses administered under compassionate use contributing to long-term survival [2] - The study titled "Rhenium Obisbemeda (REYOBIQ) in Leptomeningeal Metastases" provides additional insights from the completed Phase 1 ReSPECT-LM dose escalation trial [2] Group 2: Leptomeningeal Metastases Overview - LM is a rare but severe complication of cancer, affecting approximately 5% of cancer patients, with a notably low 1-year survival rate of 7% and a 2-year survival rate of 3% [4] - The incidence of LM is increasing, partly due to longer cancer patient lifespans and the ineffectiveness of standard chemotherapies in reaching sufficient concentrations in the cerebrospinal fluid [4] Group 3: REYOBIQ™ Mechanism and Efficacy - REYOBIQ™ is designed to deliver targeted high-dose radiation to CNS tumors, potentially improving outcomes compared to existing therapies [5] - The study reported a dose-dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space, reaching 253 Gy in Cohort 5 [6] - Clinical benefit rates were high, with 76% of patients showing complete response, partial response, or stable disease, and 87% demonstrating clinical response based on physician evaluation [6] Group 4: Clinical Trials and Funding - REYOBIQ™ is being evaluated in clinical trials for recurrent glioblastoma and leptomeningeal metastases, with funding support from the National Cancer Institute and a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [7]